StemSight

Helsinki, FI · 1 known investors

StemSight develops off-the-shelf cell therapies combining induced pluripotent stem (iPS) cells with biomaterials to address corneal blindness and limbal stem cell deficiency. The company targets patients with unmet medical needs in regenerative eye medicine.